Literature DB >> 12882834

Histamine deficiency in gene-targeted mice strongly reduces antigen-induced airway hyper-responsiveness, eosinophilia and allergen-specific IgE.

Gergely T Kozma1, György Losonczy, Márton Keszei, Zsolt Komlósi, Edit Buzás, Eva Pállinger, Judith Appel, Teréz Szabó, Pál Magyar, András Falus, Csaba Szalai.   

Abstract

Histamine is an important mediator released from activated mast cells provoked by allergen and has a substantial role in the pathophysiology of asthma. However, several lines of evidence indicate that histamine could also have important functions in the regulation of basic cell biological processes. We have used histidine decarboxylase gene-targeted (HDC-KO) mice, lacking histamine, to investigate the effect of histamine deficiency in an animal model of asthma. Our previous investigations revealed that HDC-KO mice had fewer mast cells with reduced granular content and defective degranulation characteristics. Ovalbumin (OVA)-sensitized and challenged HDC-KO mice had significantly reduced airway hyper-responsiveness, lung inflammation, bronchoalveolar lavage eosinophilia, and OVA-specific IgE compared with congenic wild-type littermates treated in the same way. Comparing the expression profiles of cytokines, the levels of IL-1alpha, IL-1beta, IL-4, IL-5, IL-6 and IFN-gamma were significantly lower in the HDC-KO mice in asthmatic late phase, indicating a significantly altered immune response to OVA provocation and challenge. Evaluation of chemokine gene expression revealed that OVA treatment caused elevation of both T(h)1- and T(h)2-type chemokines in wild-type mice, while the chemokine expression was polarized toward a T(h)1 response in HDC-KO mice. According to our results we can suggest that the possible causes of the reduced asthma symptoms in the HDC-KO mice may be the imperfect mast and eosinophil cell system, and an altered immune response to OVA provocation and challenge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882834     DOI: 10.1093/intimm/dxg095

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  The H1 histamine receptor regulates allergic lung responses.

Authors:  Paul J Bryce; Clinton B Mathias; Krista L Harrison; Takeshi Watanabe; Raif S Geha; Hans C Oettgen
Journal:  J Clin Invest       Date:  2006-05-04       Impact factor: 14.808

Review 2.  Mast cell secretory granules: armed for battle.

Authors:  Sara Wernersson; Gunnar Pejler
Journal:  Nat Rev Immunol       Date:  2014-06-06       Impact factor: 53.106

3.  The dual H3/4R antagonist thioperamide does not fully mimic the effects of the 'standard' H4R antagonist JNJ 7777120 in experimental murine asthma.

Authors:  Detlef Neumann; Silke Beermann; Heike Burhenne; Silke Glage; Christina Hartwig; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-03       Impact factor: 3.000

Review 4.  Mast Cell Interactions and Crosstalk in Regulating Allergic Inflammation.

Authors:  Tania E Velez; Paul J Bryce; Kathryn E Hulse
Journal:  Curr Allergy Asthma Rep       Date:  2018-04-17       Impact factor: 4.806

Review 5.  New developments in the use of histamine and histamine receptors.

Authors:  Craig Smuda; Paul J Bryce
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

6.  Common bacterium induces histamine production in neutrophils.

Authors:  Carol Potera
Journal:  Environ Health Perspect       Date:  2012-05       Impact factor: 9.031

7.  Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation.

Authors:  Silke Beermann; Silke Glage; Danny Jonigk; Roland Seifert; Detlef Neumann
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

8.  Neutrophil histamine contributes to inflammation in mycoplasma pneumonia.

Authors:  Xiang Xu; Dongji Zhang; Hong Zhang; Paul J Wolters; Nigel P Killeen; Brandon M Sullivan; Richard M Locksley; Clifford A Lowell; George H Caughey
Journal:  J Exp Med       Date:  2006-12-11       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.